stockrow
Saturday 7 November 2026
Export ZVRA’s income statement to Excel — free account
Zevra Therapeutics, Inc.
ZVRA Healthcare Biotechnology
Zevra Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.5 million, up 350.9% from fiscal 2024.
- Revenue
- +44.9%
- EPS
- +3,333.0%
- Free cash flow
- +106.8%
- Total debt
- +4.07%
Quarter to September 2026, against a year earlier
11.55
1.02
+9.69%
Follow ZVRA
Alert me
Zevra Therapeutics, Inc. (ZVRA) P/E ratio
As of 6 November 2026, Zevra Therapeutics, Inc. (ZVRA) trades at a P/E ratio of 9.0×. Over the past ten years it has ranged from 0.0× (September 2025) to 23.6× (October 2025); the current reading is higher than 96% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 6.5× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 8.5× | (43.37%) |
| Jun 2026 | 15.1× | 232.02% |
| Mar 2026 | 4.5× | (30.49%) |
| Dec 2025 | 6.5× | (65.61%) |
| 25 more quarters | Free account |
Against its own ten years
Low 0.0×
High 23.6×
Ten-year median
0.0×
Current reading's percentile
96
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| HELP Cybin Inc. compare | n/m |
| DSGN Design Therapeutics, Inc. compare | n/m |
| DBVT DBV Technologies S.A. compare | n/m |
| FDMT 4D Molecular Therapeutics, Inc. compare | n/m |
| SGMT Sagimet Biosciences Inc. compare | n/m |
| GERN Geron Corporation compare | n/m |
| CADL Candel Therapeutics, Inc. compare | n/m |
| WVE WAVE Life Sciences Ltd. compare | n/m |
| ZVRA Zevra Therapeutics, Inc. | 9.0× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)